Hindustan Laboratories Limited has filed its Draft Red Herring Prospectus (DRHP) with the Securities and Exchange Board of India (SEBI) for its proposed initial public offering.
The IPO comprises a total issue size of up to 14,100,000 equity shares of face value ₹10 each, including a fresh issue of up to 5,000,000 equity shares and an offer for sale of up to 9,100,000 equity shares by existing shareholders. Rajesh Vasantray Doshi, Kunjal C. Dedhia and Krishiv Rajesh Doshi are the promoters of the company.
According to the DRHP, the company proposes to utilise the net proceeds from the fresh issue towards funding working capital requirements and general corporate purposes.
Hindustan Laboratories is primarily engaged in the large-scale manufacturing and supply of generic medicines to government institutions under a business-to-government (B2G) framework. The company supplies medicines under procurement contracts awarded by central government agencies under the Ministry of Health and Family Welfare as well as various state government agencies and bodies.
The company’s products are supplied either under brand names or generic names based on customer requirements. All products, except those manufactured for third parties, carry the company’s logo. During the six months ended September 30, 2025, and in FY25, the company supplied products across 27 states and Union Territories.
The equity shares are proposed to be listed on BSE Limited and the National Stock Exchange of India Limited. Choice Capital Advisors Private Limited is the book running lead manager to the issue.
